Phase 1, Open-label, Single Dose Study to Examine Safety, Tolerability, Pharmacokinetics and Virologic Impact of VRC01LS or VRC07-523LS in HIV-infected Viremic Adults

NCT02840474 · clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
16
Enrollment
NIH
Sponsor class

Conditions

Interventions

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

Collaborators